Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer
Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer
复制标题
DOI：
10.1093/annonc/mdp062
复制
发表时间：
2009-10-01
影响因子：
50.5
通讯作者：
Lewensohn, R.
中科院分区：
文献类型：
--
作者：
Linderholm, B. K.;Hellborg, H.;Lewensohn, R.
患者和方法：VEGF水平测定的一个回顾性系列组成的679个连续的原发性乳腺癌patients.Results：87例患者（13%）被归类为TNBC和有显着较高的VEGF水平;中位值TNBC为8.2 pg/μ g DNA相比，2.7 pg/μ g DNA在非TNBC（P < 0.001）。与非TNBC患者相比，TNBC患者的无复发生存期[风险比（HR）= 1.8; P = 0.0023]、乳腺癌校正生存期（HR = 2.2; P = 0.004）和总生存期（HR = 1.8; P = 0.005）在统计学上显著缩短。TNBC患者复发早于非TNBC患者;从诊断到首次复发的平均时间分别为18.8和30.7个月。首次复发和死亡之间的时间在TNBC中也较短：7.5个月对非TNBC中的17.5个月（P = 0.087）。与非TNBC相比的VEGF水平。正在进行的临床试验将回答，如果治疗针对血管生成可能是一种替代方法，以改善预后不良组的结果。
Patients and methods: VEGF levels were determined by an enzyme immunosorbent assay in a retrospective series consisting of 679 consecutive primary breast cancer patients.Results: Eighty-seven patients (13%) were classified as TNBC and had significantly higher VEGF levels; median value in TNBC was 8.2 pg/mu g DNA compared with 2.7 pg/mu g DNA in non-TNBC (P < 0.001). Patients with TNBC had statistically significant shorter recurrence-free survival [hazard ratio (HR) = 1.8; P = 0.0023], breast cancer-corrected survival (HR = 2.2; P = 0.004) and overall survival (HR = 1.8; P = 0.005) compared with non-TNBC. Patients with TNBC relapsed earlier than non-TNBC; mean time from diagnosis to first relapse was 18.8 and 30.7 months, respectively. The time between first relapse and death was also shorter in TNBC: 7.5 months versus 17.5 months in non-TNBC (P = 0.087).Conclusions: Our results show that TNBC have higher i.t. VEGF levels compared with non-TNBC. Ongoing clinical trials will answer if therapy directed towards angiogenesis may be an alternative way to improve outcome in this poor prognosis group.